A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

Ovarian Cancer Clinical Trial

— DUETTE  

Official title:

A Phase 2 Randomized, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients With Platinum Sensitive Relapsed Epithelial Ovarian Cancer, Who Have Previously Received PARP Inhibitor Maintenance Treatment

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04239014
• Other study ID #: D6018C00004
• Status: Withdrawn
• Phase: Phase 2
• Start date: August 7, 2020
• Est. completion date: January 25, 2021

Study information

• Verified date: March 2021
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To investigate the effectiveness and tolerability of a second maintenance treatment in participants with platinum-sensitivity relapsed (PSR) epithelial ovarian cancer, who have previously received PARPi maintenance treatment and who have benefit (complete response [CR] or partial response [PR]) or stable disease (SD) from further platinum based chemotherapy.

Description:

This is a Phase II, randomised, multicentre study to investigate the efficacy and tolerability of a second maintenance treatment in participants with PSR epithelial ovarian cancer, who have previously received PARPi maintenance treatment and who have benefit (CR or PR) or SD from further platinum based chemotherapy. Participants will be recruited globally from approximately 120 study sites in the USA, Canada, Middle East and Europe. Approximately 192 participants fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomised in a 1:1:1 ratio to the following 3 treatment arms (64 participants per arm): - Arm 1 (ceralasertib+olaparib): Ceralasertib 160 mg once daily (QD) orally or per os (PO) on Days 1 to 7 plus olaparib 300 mg twice daily (BD) PO continuous (28 day cycle) - Arm 2 (olaparib monotherapy): Olaparib 300 mg BD PO daily continuous - Arm 3 (placebo): Placebo to match olaparib BD PO daily continuous The olaparib and placebo arms will be double blinded, whereas the ceralasertib+olaparib arm will be open label. It is expected that approximately 320 participants will be screened. The study achieved First Subject In date, but enrollment equals 0 as 7 participants have signed the Informed Consent Form (ICF) and were later screen failed.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 25, 2021
• Est. primary completion date: January 25, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 130 Years

Eligibility

Inclusion Criteria:

• Capable of providing signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the Clinical Study Protocol (CSP).
• Provision of signed and dated, written ICF prior to any mandatory study specific procedures, sampling, and analyses.
• Female =18 years of age at the time of signing the ICF.
• Eastern Cooperative Oncology Group performance status 0 to 1 within 28 days of randomization.
• Participants with relapsed histologically confirmed diagnosis of high grade epithelial ovarian cancer (including primary peritoneal and/or fallopian tube cancer), with disease relapse on or after completion of PARPi maintenance therapy and who have not received any intervening systemic treatment since discontinuation of PARPi (this excludes the platinum based chemotherapy received during Screening Part 1 of this study).
• A minimum of 6 months of prior PARPi treatment received in the maintenance setting for PSR ovarian cancer (a minimum of 12 months is required if the participant received PARPi maintenance following first line chemotherapy). If the prior PARPi used was olaparib then participants must have received treatment without significant toxicity or the need for a permanent dose reduction.
• Disease relapse in the second line (first relapse) or third line (second relapse) setting.
• Able to provide and consent to the collection of a contemporaneous tumor tissue biopsy and blood sample.
• Able to provide a Formalin Fixed Paraffin Embedded archival tumour tissue block from the time of primary tumour diagnosis (taken ideally prior to receiving any systemic treatment, and definitely prior to first PARPi treatment) for prospective Breast cancer susceptibility gene (BRCA) status testing. If tumour blocks are unavailable, tissue sections are acceptable with a minimum requirement of at least 20 unstained sections on uncharged slides without cover slips. Fine needle aspirates are not acceptable.
• Where the patient has previously been tested for germline or somatic BRCA alterations using a verified and well-validated test in line with local regulations, performed in a locally accredited laboratory (eg, College of American Pathologists/Clinical Laboratory Improvement Amendments laboratory, where available), and signed consent to provide a copy of the BRCA report.
• Platinum-sensitive disease at the time of disease relapse, i.e, platinum-treatment free survival of greater than 6 months as defined by the Gynecological Cancer Intergroup (Wilson et al 2017).
• For the platinum-based chemotherapy course received following pre screening (Part 1) and prior to entering the main screening (Part 2).
• Any prior palliative radiation must have been completed at least 7 days prior to the start of study drugs, and participants must have recovered from any acute adverse effects prior to the start of study treatment.
• Normal organ and bone marrow function measured within 28 days prior to randomization.
• Participant is willing and able to comply with the CSP for the duration of the study including undergoing treatment and scheduled visits and examinations.
• Participants must have a life expectancy of =16 weeks.
• Participants must be able to swallow tablets whole.
• For inclusion in the optional (deoxyribonucleic acid) genetics research, study participants must fulfil the following criterion: Provide informed consent for the genetic sampling and analyses. If a participant declines to participate in the genetics research, there will be no penalty or loss of benefit to the participant. A participant who declines genetics research participation will not be excluded from any other aspect of the main study.
• Participant's body weight must be >30 kg.
• Postmenopausal or evidence of non-childbearing status for women of childbearing potential.
• Women of childbearing potential and their partners, who are sexually active, must agree to the use of 2 highly effective forms of contraception in combination from the signing of the informed consent (Screening Part 1), throughout the period of taking study treatment and for at least 6 months after the last dose of study drug(s).

Exclusion Criteria:

• Participants who have had drainage of their ascites during the final 2 cycles of their last chemotherapy regimen or during the period between completion of chemotherapy and first dose of study treatment.
• Participants with current signs or symptoms of bowel obstruction, including sub-occlusive disease, related to underlying disease.
• History of leptomeningeal carcinomatosis.
• Participants with symptomatic uncontrolled brain metastases.

1. A scan to confirm the absence of brain metastases is not required.

2. Participants whose brain metastases have been treated may participate provided they show radiographic stability. In addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have resolved or be stable (Common Terminology Criteria for Adverse Events [CTCAE] Grade <2) either, without the use of steroids, or are stable on a steroid dose of =10 mg/day of prednisone or its equivalent and stable on anti convulsants if required for at least 14 days prior to the start of treatment.

3. Participants with spinal cord compression are not eligible unless considered to have received definitive treatment for this and have evidence of clinically SD for >28 days and have not received steroid treatment for at least 14 days prior to the start of study treatment.

• History of another primary malignancy except for:

1. Malignancy treated with curative intent and with no known active disease =5 years before the first dose of IP and of low potential risk for recurrence;

2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease;

3. Adequately treated carcinoma in situ without evidence of disease.

• Major surgical procedures (as defined by the investigator) =28 days of beginning study treatment, or minor surgical procedures =7 days. No waiting period required following port a cath or other central venous access placement.
• Persistent toxicities (=CTCAE Grade 2) caused by previous cancer therapy, excluding alopecia and CTCAE Grade 2 peripheral neuropathy. Note: participants with signs of ongoing complications from radiation therapy are not eligible for this study.
• Participants with myelodysplastic syndrome (MDS) /acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
• Resting electrocardiogram indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator, or participants with congenital long QT syndrome.
• Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
• History of allogeneic organ transplantation including previous allogeneic bone marrow transplant or double umbilical cord blood transplantation.
• History of active primary immunodeficiency.
• Active infection including tuberculosis (TB), hepatitis B (known positive hepatitis B virus [HBV] surface antigen [HBsAg] result), hepatitis C (HCV), or human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies). Participants with a past or resolved HBV infection are eligible. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid.
• Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations.
• Current dependency on total parenteral nutrition or intravenous (iv) fluid hydration.
• Whole blood transfusions in the last 120 days prior to entry to the study.
• Cytotoxic chemotherapy, hormonal or non hormonal targeted therapy within 21 days of Cycle 1, Day 1 is not permitted. The participant can receive a stable dose of bisphosphonates or denosumab for bone metastases, before and during the study as long as these were started at least 5 days prior to study treatment.
• Participation in another clinical study with an IP during the chemotherapy course immediately prior to randomisation or during the course of the study.
• Previous treatment with ceralasertib or other ataxia telangiectasia and Rad3-related protein, Checkpoint kinase 1 or deoxyribonucleic acid damage response inhibitor (excluding PARPi).
• Exposure to a small molecule IP within 30 days or 5 half-lives (whichever is longer) prior to randomization. The minimum washout period for immunotherapy and bevacizumab shall be 42 days.
• Receipt of live attenuated vaccine within 30 days prior to the first dose of study treatment.
• Concomitant use of known strong cytochrome P450 (CYP) 3A inhibitors or moderate CYP3A inhibitors. The required washout period prior to starting study treatment is 2 weeks.
• Concomitant use of known strong CYP3A inducers or moderate CYP3A inducers. The required washout period prior to starting study treatment is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
• Involvement in the planning and/or conduct of the study (applies to Sponsor staff and/or staff at the study site).
• Previous randomization in the present study.
• Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.
• Pregnant or lactating women.

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Ovarian Cancer
• Ovarian Neoplasms

Intervention

Drug:
• Olaparib
Olaparib 300 mg BD (2 × 150 mg tablets) continually in the olaparib monotherapy and ceralasertib+olaparib treatment arms.
• Ceralasertib
Ceralasertib 160 mg QD (2 × 80 mg tablets) from Days 1 to 7 (inclusive) of every 28-day cycle.
• Placebo to match olaparib
Per olaparib

Locations

Country	Name	City	State
Canada	Research Site	Montreal	Quebec
Canada	Research Site	Toronto	Ontario
Italy	Research Site	Napoli
Spain	Research Site	Barcelona
United States	Research Site	Abington	Pennsylvania
United States	Research Site	Anchorage	Alaska
United States	Research Site	Atlanta	Georgia
United States	Research Site	Cleveland	Ohio
United States	Research Site	Covington	Louisiana
United States	Research Site	Florham Park	New Jersey
United States	Research Site	Hartford	Connecticut
United States	Research Site	Houston	Texas
United States	Research Site	La Jolla	California
United States	Research Site	Long Beach	California
United States	Research Site	Los Angeles	California
United States	Research Site	Louisville	Kentucky
United States	Research Site	Oklahoma City	Oklahoma
United States	Research Site	Philadelphia	Pennsylvania
United States	Research Site	Portland	Oregon
United States	Research Site	Seattle	Washington
United States	Research Site	Sioux Falls	South Dakota
United States	Research Site	Sioux Falls	South Dakota
United States	Research Site	Tampa	Florida
United States	Research Site	Teaneck	New Jersey
United States	Research Site	Tulsa	Oklahoma
United States	Research Site	West Hollywood	California

Sponsors (2)

Lead Sponsor	Collaborator
AstraZeneca	Parexel

Countries where clinical trial is conducted

United States,  Canada,  Italy,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of participants with adverse events (AEs)	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal physical examination	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal Eastern Cooperative Oncology Group (ECOG) performance status (PS)	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number participants with abnormal systolic and diastolic blood pressure	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal pulse	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal body temperature	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal electrocardiogram	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal hemoglobin (Hb)	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal leukocyte count	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal absolute neutrophil count (ANC)	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal absolute lymphocyte count	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal platelet count	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal mean cell volume	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal serum creatinine	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal serum total bilirubin	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal serum potassium, calcium and sodium	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal plasma glucose	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal serum lactate dehydrogenase	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal creatinine clearance	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal serum urea or blood urea nitrogen	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal plasma total protein	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal urine Hb/erythrocytes/blood	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal urine protein/albumin	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal urine glucose	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal urine ketones	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal urine pH	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal specific gravity	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Number of participants with abnormal urine bilirubin	To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	European quality of life 5 dimensions, 5 level	To assess both European quality of life descriptive system and European quality of life visual analogue scale (EQ VAS).; The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The participant is asked to indicate his health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the participant's health state.; The EQ VAS records the participant's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'the best health you can imagine' and 'the worst health you can imagine'.	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)	To assess tolerability from the participants perspective. PRO-CTCAE is an item library of symptomatic AEs experienced by patients while undergoing treatment of their cancer. PRO questionnaires completed at site visits must be completed prior to treatment administration	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Patient global impression of severity	To assess overall severity of participant's cancer symptoms over the past week. The item is rated using a 6 point verbal rating scale from "No Symptoms" to "Very Severe".	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Patient global impression of change	To assess overall change in health condition since the start of study treatment(s). The item is rated using a 7 point Likert type scale from "Much Better" to "Much Worse".	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Patient global impression-treatment tolerability	To asses overall bother associated with symptomatic AEs. The item is rated using a 6 point verbal scale from "Not at All" to "Very Much".	From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Other	Patient global impression-benefit risk	To asses the participant's perception of the overall benefits and risks of treatment. The 5 items to be assessed included overall trial experience, efficacy, side effects, convenience, and overall assessment of the benefits and harms of treatment. Items are rated on 5 or 6 point verbal rating or Likert type scales.	From Cycle 1 Day 1 to 12 weeks and 16 weeks of study medication.
Primary	Progression free survival (PFS)	To assess the efficacy of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	To assess from the time of randomization until the date of objective disease progression or death (by any cause in the absence of progression) or approximately up to 2.5 years.
Secondary	Overall survival (OS)	To further assess the efficacy of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo; and to assess the efficacy of maintenance ceralasertib+olaparib combination therapy compared with olaparib monotherapy.	To assess every 8 weeks (±7 days) for first 72 weeks following objective disease progression or treatment discontinuation and then every 12 weeks, up to approximately 2.5 years.
Secondary	Time to second progression	To further assess the efficacy of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo; and to assess the efficacy of maintenance ceralasertib+olaparib combination therapy compared with olaparib monotherapy. A participant's second progression status is defined according to the local standard clinical practice and may involve any of; investigator assessment of radiological progression, cancer antigen 125 (CA 125) progression, symptomatic progression or death.	To assess every 8 weeks (±7 days) for first 72 weeks following objective disease progression or treatment discontinuation and then every 12 weeks, up to approximately 2.5 years.
Secondary	Objective response rate	To further assess the efficacy of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo; and to assess the efficacy of maintenance ceralasertib+olaparib combination therapy compared with olaparib monotherapy.	At baseline, every 8 weeks for first 72 weeks, then every 12 weeks after randomization until objective disease progression or approximately up to 2.5 years.
Secondary	Duration of response	To further assess the efficacy of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo; and to assess the efficacy of maintenance ceralasertib+olaparib combination therapy compared with olaparib monotherapy.	At baseline, every 8 weeks for first 72 weeks, then every 12 weeks after randomization until objective disease progression or approximately up to 2.5 years.
Secondary	Percentage change in tumour size	To further assess the efficacy of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.	At baseline, every 8 weeks for first 72 weeks, then every 12 weeks after randomization until objective disease progression or approximately up to 2.5 years.
Secondary	Plasma concentration data for olaparib and ceralasertib	To evaluate the pharmacokinetic (PK) exposure of ceralasertib+olaparib combination therapy.	At cycle 1 Day 1 and Day 7
Secondary	Change from baseline in European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ) C30	To assess the impact of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo on participants' symptoms, functioning, and Health-related quality of life (HRQoL). Questions are grouped into functional scales, symptom scales, a global health status / quality of life (QoL) scale, assessing additional symptoms commonly reported by cancer participants, and the financial impact of the disease. All but 2 questions are rated on a 4 point verbal rating scale: "Not at all," "A little," "Quite a bit," and "Very much." The 2 questions concerning global health status and QoL have 7 point scales with ratings ranging from "Very poor" to "Excellent." For each of the 15 domains, final scores are transformed such that they range from 0 to 100, where higher scores indicate better functioning, better QoL, or worse symptoms.	At Cycle1 Day 1, every 4 weeks from Cycle 1 Day 1 until treatment discontinuation, and follow-up 30 days after last dose of study medication.
Secondary	Change from baseline in EORTC-QLQ-OV28	To assess the impact of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo on participants' symptoms, functioning, and HRQoL It consists of 28 items assessing abdominal/gastrointestinal symptoms (6 items), peripheral neuropathy (2 items), other chemotherapy side effects (5 items), hormonal symptoms (2 items), body image (2 items), attitudes to disease/treatment (3 items), sexuality (4 items) and 4 other single items. All questions are rated on a 4 point verbal rating scale: "Not at all," "A little," "Quite a bit," and "Very much." Final scores are transformed such that they range from 0 to 100, where higher scores indicate greater functioning, greater QoL, or greater level of symptoms.	At Cycle1 Day 1, every 4 weeks from Cycle 1 Day 1 until treatment discontinuation, and follow-up 30 days after last dose of study medication.
Secondary	Time to earliest progression by RECIST 1.1 or CA-125 or death	Time to progression by RECIST 1.1 or CA-125 progression or death is defined as the time from randomisation to the earlier date of RECIST 1.1 or CA-125 progression or death by any cause.	At baseline, every 8 weeks for first 72 weeks, then every 12 weeks after randomization until objective disease progression or approximately up to 2.5 years.